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Background: This study aimed to investigate the benefits of administering perioperative high-dose prednisolone in
conjunction with thymectomy in patients with myasthenia gravis.
Methods: We retrospectively reviewed data from patients with Myasthenia Gravis Foundation of America Clinical
Class I to IIIB who had undergone an extended thymectomy between 1992 and 2009. Perioperative high-dose
prednisolone was administered at starting doses of 10 to 20 mg and escalated up to 100 mg on alternate days. The
treatment group comprised 70 patients receiving perioperative high-dose prednisolone, whereas the control group
included 61 patients not treated with preoperative steroids. The two groups were compared with respect to
baseline clinical characteristics, incidence of postoperative complications, and follow-up disease status.
Results: Prednisolone-treated patients presented with more advanced disease compared to controls (Class IIB or
greater, 42 [60.0%] versus 7 [11.3%], respectively; P < 0.001). Mean preoperative%FVC was lower and FEV1.0% was
higher in treated patients than in controls (%FVC: 92.4 ± 2.3% versus 99.5 ± 2.4%, respectively; P = 0.037, FEV1.0%:
85.2 ± 1.3% versus 81.4 ± 0.9%, respectively; P = 0.017). The groups were similar in other variables including presence
of thymoma, and operative procedure. In the treatment group, disease status was significantly improved only by
the induction of high-dose prednisolone before the surgery (P < 0.001), and these patients discontinued anti-
cholinesterase therapy more frequently than controls (P < 0.001). Moreover, the treatment group demonstrated
markedly lower rates of postoperative crisis (12.2% versus 2.9%, respectively; P = 0.045). The incidence of infection,
wound dehiscence, and diabetes mellitus were comparable between groups. Survival analysis demonstrated higher
rates of treated patients with improved disease status at three and five years (92% and 96%, respectively) compared
to controls (57% and 76%, respectively; P < 0.001). Likewise, significantly greater proportions of treated patients
achieved complete stable remission or pharmacologic remission at three, five, and ten years (23%, 42%, and 72%,
respectively) compared to controls (10%, 20%, and 44%, respectively; P = 0.002).
Conclusions: Perioperative high-dose prednisolone therapy is a safe, promising strategy for managing patients with
myasthenia gravis and may reduce the incidence of postoperative crisis while improving disease status.
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Myasthenia gravis (MG) is an autoimmune disease
caused by acetylcholine receptor antibodies (AchR-Ab)
that block acetylcholine receptors (AchR) at the postsyn-
aptic neuromuscular junction. In 1935, Simon demon-
strated the efficacy of percutaneous adrenocorticotropic
hormone [1] and in 1939 Blalock and colleagues es-
poused the value of thymectomy [2]. Subsequently, fur-
ther advancements in immunosuppressive therapy and
thymectomy have formed the mainstay of treatment for
MG [3,4]. However, given the paucity of strong evidence
supporting the utility of thymectomy in the management
of MG, standard treatment guidelines have not yet been
established [5].
In our institution, preoperative stabilization of MG is
considered essential for preventing postoperative disease
crisis and achieving early remission. Thus, a multimodal
approach including a regimen of prednisolone (PSL)
combined with extended thymectomy has been pro-
posed. In 1978, we implemented a strategy of preopera-
tive high-dose PSL therapy followed by extended
thymectomy for MG patients, which produced favorable
results [4,6]. However, whether administering a peri-
operative regimen of steroids during thymectomy con-
fers superior benefits over thymectomy alone remains
undetermined. Therefore, we conducted a retrospective
analysis in order to investigate the clinical benefits of




We retrospectively reviewed records from 180 patients
who had been diagnosed with MG and had undergone
extended thymectomy between 1992 and 2009. Detailed
data were prospectively collected at the time of hospital
discharge and from outpatient charts, and included
information on patient characteristics, medical history,
neurologic findings, disease status, the presence of thym-
oma, use of immunosuppressive therapies (i.e., PSL or
tacrolimus) and anti-cholinesterase agents, induction
with plasma exchange, operative procedures, postopera-
tive complications, pathologic diagnosis, and follow-up
disease status. Regarding the patients evaluated before
the year 2000, when the Myasthenia Gravis Foundation
of America (MGFA) classification was introduced, we
redefined the MGFA class according to the clinical re-
cords, including thorough data of neurologic findings.
We included patients considered to have MGFA Class I
to IIIB and excluded very severe cases, such as MGFA
Class IV or V, because the variability and complexity of
therapies for these latter cases made it difficult to evalu-
ate the efficacy of the perioperative prednisolone therapy
alone. Eligible patients were divided into two groups.The ph-PSL group comprised patients who had received
perioperative high-dose PSL according to the protocol
described below. The control group consisted of patients
who had not received steroidal treatment preoperatively.
Patients with a history of immunosuppressive agent use
such as steroids were also excluded; only patients who
were administered steroids as part of the “preoperative
high-dose prednisolone therapy protocol” were included
in the research group. The two groups were compared
on the basis of clinical characteristics, the incidence of
postoperative MG crisis and other complications, and
follow-up disease status.
Indication for treatment with high-dose PSL
After the diagnosis of MG, informed consent was obtained
from each patient and medical treatment was initiated.
Depending on the patient’s age, clinical history, MG status,
and the presence of thymoma, the neurologists considered
therapeutic options including the administration of
anti-cholinesterase, high-dose PSL, thymectomy, intra-
venous immunoglobulin, and/or plasma exchange.
Patients with less severe MG such as MGFA I or IIA
were likely to undergo only thymectomy with or without
anti-cholinesterase. In cases with advanced thymoma,
thymectomy was considered a priority, and high-dose PSL
was not administered. Patients with severe MG status, in-
cluding MGFA IIB or more were likely to have ph-PSL
therapy after obtaining the patients’ consent.
The operative method was extended thymectomy in
all cases, regardless of open chest surgery with sternot-
omy or video-assisted thoracoscopic surgery (VATS).
Extended thymectomy consisted of thymectomy with
removal of all mediastinal fatty tissue between the two
bilateral phrenic nerves from the top of the horns of the
thymus to the diaphragm.
Treatment protocol for ph-PSL
In order to manage the risk of worsening MG symptoms
due to steroid effects, oral PSL was initiated at 10 to
20 mg and gradually escalated to 100 mg on alternate
days. Once patients had achieved stable disease status
and had been maintained on high-dose PSL for two to
four weeks, extended thymectomy was performed. When
anti-cholinesterase was used as an initial treatment, it
was reduced and discontinued after stabilization on PSL
therapy. Histamine H2 blocker, vitamin D, and potas-
sium were routinely administered to all patients for
prophylaxis of adverse steroid effects. Postoperatively,
the PSL dose was tapered by 5 mg per month over a
minimum period of two years.
Patient follow up and evaluation of outcomes
MG crisis was defined as an exacerbation of disease
necessitating any of the following: (1) re-intubation, (2)
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additional plasma exchange. Data on other postoperative
complications, including infection, wound dehiscence,
diabetes mellitus, hyperlipidemia, osteoporosis, cataract,
and depression, were also collected from the clinical
records and evaluated.
All patients were followed for a minimum of three years.
Postoperative MG status was assessed annually using the
criteria cited by Jaretzki et al. [7]. “Improved” (Imp) was
defined as a substantial decrease in pretreatment clinical
manifestations or a sustained substantial reduction in MG
medications. “Complete Stable Remission” (CSR) signified
the absence of MG symptoms or signs for at least one year
without treatment for MG during this period. Patients who
met the former criteria for CSR but continued to take some
form of treatment for MG were considered to have
achieved “Pharmacologic Remission” (PR).
Statistical analysis
The data were expressed as the mean and standard devi-
ation. Differences between the treatment and control
groups were examined using Fisher’s exact test and a chi-
square test for categorical variables and the unpaired t-test
for continuous variables. Survival analysis using the Kaplan
Meier method was employed to examine the proportions
of patients with Imp, CSR, and PR +CSR responses over
time. The log-rank test was applied to detect the differences
in the long-term outcomes between the groups. A P-value ≤
0.05 was considered statistically significant.
Ethics review
Prior to the study, the ethics review board of our institu-
tion examined and approved our research protocol as












Figure 1 Histogram of MG patients by prednisolone dose. Values on t
the y-axis indicate the dose of preoperative PSL administered on alternate
on the z-axis. Black bars indicate patients who were included in the ph-PSL
white bars indicate patients excluded from the study due to low-dose predResults
Patient characteristics
Of the 180 patients with MG, 70 patients comprised the
ph-PSL group. Sixty-one patients who did not receive
any preoperative steroid treatment were included in the
control group. The remaining 49 patients were excluded
due to either treatment with PSL doses <100 mg on al-
ternate days, previous record of treatments with steroids
or immunosuppressive agents, MGFA Class ≥ IV, and/or
insufficient information. Figure 1 shows the patients
grouped by the inclusion criteria. Table 1 summarizes
the baseline patient characteristics. At study entry, MG
disease severity was significantly greater in the ph-PSL
group compared to the control group (MGFA Class ≥
IIB, 42 [60.0%] versus 7 [11.3%], respectively; P < 0.001).
Compared to controls, patients in the ph-PSL group
demonstrated a significant reduction in the mean pre-
operative%FVC (92.4 ± 18.4% versus 99.5 ± 18.9%, re-
spectively, P =0.037) as well as a marked increase in the
mean preoperative FEV1.0% (85.2 ± 10.2% versus 81.4 ±
6.9%, respectively, P = 0.017). However, the two groups
did not differ significantly with regards to other clinical
features such as age, sex, serum level of acetylcholine
receptor antibody, treatment with anti-cholinesterase
and tacrolimus, the presence of thymoma, and operative
procedure including thoracotomy with sternotomy or
video-assisted thoracoscopic surgery.
Clinical course of PSL treatments
Figure 2 shows the numbers of patients in each group
receiving various types of treatment during the study
period. In the ph-PSL group, 30 patients were treated
with intravenous immunoglobulin and/or plasma ex-









he x-axis represent MGFA Class at the initial diagnosis of MG. Values on
days. The corresponding numbers of patients are represented by values
group. Gray bars signify those included in the control group, and
nisolone treatment.
Table 1 Patient characteristics
ph-PSL (n = 70) Control (n = 61) P-value
Age, years† 46.9 ± 17.4 51.3 ± 13.9 0.115
Sex, n, male/female 21/49 20/41 0.732
Preoperative%FVC† 92.4 ± 18.4 99.5 ± 18.9 0.037*
Preoperative FEV 1.0%† 85.2 ± 10.2 81.4 ± 6.9 0.017*
Initial MGFA Class I/IIA/
IIB/IIIA/IIIB, n
0/28/17/9/16 25/29/5/1/1
Initial MGFA Class I +
IIA/IIB + IIIA + IIIB, n
28/42 54/7 <0.001*












†Values represent mean ± standard deviation achR-Ab, acetylcholine receptor
antibody; anti-ChE, anti-cholinesterase; FEV, forced expiratory volume; FVC,
forced vital capacity; MGFA, Myasthenia Gravis Foundation of America; VATS,
video-assisted thoracoscopic surgery.
Yamada et al. Journal of Cardiothoracic Surgery 2013, 8:226 Page 4 of 8
http://www.cardiothoracicsurgery.org/content/8/1/226patients received ph-PSL only. Following surgery, PSL
was withdrawn in 44 patients due to disease improve-
ment while 20 patients continued on PSL. Although
none of the patients in the control group received
additional preoperative treatment with the exception of
anti-cholinesterase, 25 patients in this group initiated
PSL postoperatively due to worsening of MG.
Preoperative stabilization of MG with PSL
In the ph-PSL group, MG status was well-stabilized
during the preoperative period to the extent that in
most cases, MGFA class was significantly improved


















Figure 2 Clinical course of steroid treatments for study groups: (a) phwas withdrawn. Of the 47 patients initiating anti-
cholinesterase in combination with PSL, 18 patients
discontinued anti-cholinesterase before surgery (cessa-
tion rate: 38.3%) and 24 discontinued treatment post-
operatively (total cessation rate: 89.4%). In contrast,
of the 33 controls commencing anti-cholinesterase
therapy, only one patient (3%) was able to stop the
medication preoperatively and 19 others discontinued
treatment after surgery (total cessation rate: 60.6%).
Overall, anticholinesterase therapy was withdrawn sig-
nificantly more frequently in the ph-PSL group than in
the control group during both the preoperative phase
(P < 0.001) and the postoperative phase (P = 0.002).
Postoperative complications including MG crisis
There were no intraoperative deaths in either group.
Table 2 lists the frequency of postoperative complica-
tions occurring during hospitalization. Significantly
fewer patients in the ph-PSL group experienced postop-
erative MG crisis compared to the control group (2
[2.9%] versus 8 [12.9%], respectively; P = 0.045). Pneu-
monia and wound infection accounted for three cases
each in the control group but no such events occurred
in the ph-PSL group (P = 0.098, P = 0.098, respectively).
Four patients in the ph-PSL group and one patient in
the control group developed wound dehiscence; how-
ever, the difference in the frequency between the groups
was not significant (P = 0.368). Likewise, there were no
significant differences between the groups in the fre-
quency of steroid-related complications such as diabetes
mellitus, hyperlipidemia, osteoporosis and cataract, fol-
lowing discharge (P = 0.303, P = 0.283, P = 1.000, P =
1.000, respectively) (Table 3).
Clinical outcomes
Patients were followed for a mean period of 6.9 ±

































(a) Before initial 
treatment
(b) Following initial 
treatment (preoperative)
P<0.001
(n, %) (n, %)
Figure 3 Distribution of the MG patients: (a) MGFA class at first presentation and (b) preoperative MGFA classes after the
initial treatment.
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group compared to 57% and 76%, respectively, in the
control group (P < 0.001) (Figure 4a). MG status among
patients in the ph-PSL group improved more rapidly
compared to the control group. The three-, five-, and
ten-year rates of “CSR” were 0, 26%, and 44%, respect-
ively, in the ph-PSL group compared to 6%, 16%, and
36%, respectively, in the control group (Figure 4b).
Patients in the ph-PSL group tended to achieve CSR,
but the proportions of patients attaining CSR at each
interval did not differ significantly from those of the
control group (P = 0.257). In contrast, significantly
greater proportions of patients in the ph-PSL group
achieved “CSR + PR” at three, five, and ten years (23%,
42%, and 72%, respectively) compared to controls
(10%, 20%, and 44%, respectively; P = 0.002) (Figure 4c).
Patients in the ph-PSL group appeared to achieve “CSR
+ PR” more readily than those in the control group.
Discussion
Although patients receiving ph-PSL presented with
greater disease severity compared to controls, the inci-
dence of MG crisis was significantly lower in the former
group due to effective preoperative stabilization of MGTable 2 Postoperative surgical complications during
hospitalization
ph-PSL (n = 70) Control (n = 61) P-value
Myasthenia gravis crisis 2 8 0.045*
Infection
Pneumonia 0 3 0.098
Wound infection 0 3 0.098
Wound dehiscence 4 1 0.368
Values represent number of cases.
*Statistically significant difference.with high-dose PSL therapy. The frequency of steroid-
related complications, including postoperative infection,
wound dehiscence diabetes mellitus, hyperlipidemia and
cataract, appeared to be similar in both groups. Further-
more, administering high-dose PSL therapy was more
likely to improve postoperative MG status for a long-
term period, suggesting that early induction with an im-
munosuppressant can modify the course of the disease.
MG crisis is the most severe phenotype, characterized
by respiratory failure requiring invasive or noninvasive
mechanical ventilation. Approximately 15 to 20% of pa-
tients with MG experience crisis in their lifetime, typic-
ally within the first two years of the diagnosis [8].
Alshekhlee et al. estimated that in a large US cohort, the
overall in-hospital mortality rate in patients experiencing
MG crisis was approximately 4.5%, which was higher
than that in patients without MG crisis (2.2%). Along
with other factors, including age and respiratory failure
requiring endotracheal intubation, the diagnosis of MG
crisis is a major predictor of mortality [9]. Because sur-
gery is a recognized trigger, MG crisis is considered to
be one of the most serious postoperative complications.
Thus, preventing postoperative MG crisis is a key con-
cern among general thoracic surgeons and neurologists.
Accordingly, the effectiveness of preoperative ster-
oidal treatment for MG patients has been investigated
for several decades [10,11]. The rationale for imple-
menting induction steroid therapy combined with
extended thymectomy may be explained as follows. An
induction of steroidal agents attenuates serum AchR-
Ab and stabilizes MG status [12]. With stabilization,
anti-cholinesterase treatment can be withdrawn or re-
duced. In turn, discontinuation of anti-cholinesterase
revives and stabilizes the function of AchR. Stabilizing
MG status allows invasive surgical treatment to be
performed safely.







Impaired glucose tolerance 3 6 0.303
Diabetes mellitus 3 6 0.303
Hyperlipidemia 6 2 0.283
Osteoporosis 2 1 1.000
Cataract 1 0 1.000
Values represent number of cases.
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tients who were treated with preoperative prednisone in
combination with thymectomy [13]. Several other stud-
ies have evaluated various steroid regimens as well.
Warmots et al. and other researchers reported high
response rates and lower morbidity for patients treated
with an alternate-day regimen of prednisone [14].
Seybold et al. purported that gradually increasing the
dose of prednisone during therapy reduced the risk of
worsening disease in MG patients initiating steroid treat-
ment [3]. Combining these approaches, Bolooki et al.
found that high-dose steroid therapy was efficacious in
the perioperative management of MG patients undergo-
ing thymectomy [15]. Recently, Klimek-Piotrowska et al.
reported the findings of a prospective autopsy study and
confirmed that ectopic thymic tissues frequently exist in
the mediastinum beyond the confines of the surgical
field [16], suggesting a limitation of surgical approaches
for this disease and a necessity for multimodal therapy.
Based on the findings of these previous studies, we
started offering perioperative high-dose PSL therapy
followed by extended thymectomy in 1978 for MG
patients in order to stabilize perioperative MG status,
prevent postoperative MG crisis, and achieve early dis-
ease remission. Our experience, as presented in thisP < 0.001
% %
(a) (b)
Figure 4 Comparison of clinical outcomes (time to “Improved,” “CSR,
and (c) “CSR + PR”.study, provides further evidence supporting the effective-
ness of this therapy.
It is important to examine the frequency of steroid
side effects in our study. Although we found these types
of complications in the ph-PSL group, the incidence of
such adverse effects was nearly identical to that in the
control group (Tables 2 and 3). Numerous studies exam-
ining the outcomes of perioperative steroid therapy dur-
ing thymectomy for MG patients have reported similar
results [4,6,17,18]. We offer several possible explanations
for these findings. Complications during hospitalization
such as wound infection or wound dehiscence may have
been attributed to the comparably lower cumulative
dose of PSL. The induction of the PSL treatment com-
menced about two months prior to surgery, and the total
cumulative dose of PSL at the time of surgery was ap-
proximately 2,000 mg. According to a study of ulcerative
colitis patients, total prednisolone doses ≥10,000 mg
may be a risk factor of surgical site infection [19]. Com-
pared to colorectal surgery, thymectomy is less likely to
be associated with infection due to the different environ-
ment of microorganisms. Thus, at the time of surgery,
the cumulative dose of PSL may not have been excessive
for this patient group. Regarding complications following
discharge, such as steroid-induced diabetes, it has been
previously reported that total glucocorticoid dose and
duration of therapy are strong predictors of diabetes in-
duction [20]. However, a study of patients with neuro-
logic disease by Iwamoto et al. found no difference in
the cumulative PSL doses between patients with or
without steroid-induced diabetes [21]. The authors sug-
gested that when patients received high-dose, short-term
steroid therapy, cumulative doses of steroids were min-
imally associated with adverse effects. However, a precise
mechanism was not described. Nevertheless, appropriate
management of patients receiving steroid therapy is
important. We deem that administering a Histamine H2P = 0.257 P = 0.002
%
(c)
” and “CSR + PR”) between study groups. (a) “Improved,” (b) “CSR,”
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cose tolerance, and offering medical advice might assist
in preventing steroid-induced diabetes. In this study,
steroid-related complications did not occur.
On the other hand, some clinicians advocate initiating
steroid therapy only after an exacerbation of MG, due to
concerns over steroid side effects [22]. We disagree with
this point of view because delayed immunosuppression
may produce a less complete response [23,24]. Indeed,
in the control group of our study, 25 of 61 (40%)
patients received steroids after thymectomy due to un-
stable postoperative disease, and half had continued the
medication at the time of our investigation. Once MG
exacerbation occurs, patients are likely to be resistant to
treatments. Our study demonstrated that contrary to
these opinions, perioperative high-dose PSL therapy was
effective and led to fewer steroidal side effects. We
strongly believe that preoperative induction with high-
dose PSL therapy should be recommended as part of the
surgical protocol.
However, routine administration of high-dose PSL
followed by thymectomy for all MG patients without
any consideration is not justified. For example, during
the early phase of the disease in mild MG cases, the
germinal centers in thymus are not developed, and
therefore, preoperative steroid therapy might not be re-
quired [25]. Moreover, even thymectomy for class I MG
remains controversial [26]. In fact, most cases in the
control group did not experience crisis or exacerbation
of MG even when they had not received any preopera-
tive PSL therapy. In our institution, the criteria for insti-
tuting PSL therapy in surgical MG patients are based on
patient characteristics, disease severity, and the presence
of advanced thymoma. Decisions regarding induction
therapy should be made only after careful assessment of
these factors.
The appropriateness of using an alternate-day regimen
of PSL 100 mg for immunosuppression must also be de-
termined. This regimen was implemented based on in-
formation in the literature and our experience but it has
not been validated by clinical trials. Although the fre-
quency of steroid-related adverse events in the ph-PSL
group in this study was similar to that in the control
group, the efficacy and minimum dose required for PSL
should be further investigated. Currently, we are con-
ducting an ongoing clinical study in order to evaluate
whether an induction of tacrolimus can reduce the
dosage of PSL in MG surgical patients.
Authors from our group have previously reported the
outcomes of PSL therapy [4,6]; likewise, researchers
from other institutions have produced similar reports
[17,18]. Our present findings strengthened the evidence
supporting the clinical benefits of administering high-
dose PSL perioperatively in conjunction with extendedthymectomy. Comparing a large sample of MG patients
with or without preoperative PSL therapy is also advan-
tageous over extant published studies, wherein compari-
sons were not performed, or if so, the studies employed
inconsistent dosages of PSL and smaller sample sizes.
This study is limited by its retrospective design. Al-
though we employed specific eligibility criteria for the
high-dose PSL therapy, some amount of selection bias
existed. However, our research may be justified for two
reasons. First, in this comparative study, the ph-PSL
group, which represented a disadvantaged patient popu-
lation with more severe disease, demonstrated superior
outcomes with regard to the development of MG crisis.
Thus, despite the differences between the patient groups,
the results of this study are nevertheless noteworthy.
Second, long-term follow-up of MG patients requires a
protracted period of time, making a longitudinal study
difficult to conduct. However, plans for a prospective
study in currently underway, as described previously.
Nevertheless, we believe that this present study offers
supportive evidence and noteworthy information.
In clinical practice, the dosage of PSL varied depend-
ing on the patients’ characteristics, MG status, and
concomitant diseases (Figure 1). Although most cases
receiving steroid therapy were treated with an alternate-
day regimen of 100 mg, some had received 90 mg or
less. To avoid ambiguity in the data, the inclusion
criteria for the ph-PSL group specified a PSL dose of
100 mg on alternate days, whereas patients in the con-
trol group who received lower PSL doses and those who
had received previous steroidal therapy were excluded.
Conclusion
Perioperative high-dose PSL therapy is a promising strat-
egy for managing MG patients in terms of reducing the
incidence of postoperative MG crisis and providing
long-term disease control. However, a prospective ran-
domized study in a multicenter setting is warranted in
order to confirm the efficacy and safety of this approach.
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